2021
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefit
2020
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.Peer-Reviewed Original ResearchConceptsPD-L1 positivity ratePD-L1 positivityPD-L1 expressionDifferent metastatic sitesPrimary tumorMetastatic sitesPositivity rateImmune cellsMetastatic lesionsTumor cellsPD-L1 protein expressionTriple-negative breast cancerMore primary tumorsTriple negative breast cancer tumorsPrimary breast lesionsPrimary outcome measureSoft tissueNegative breast cancerLow positivity rateBreast cancer tumorsBone metastasesFoundation MedicineLymph nodesPD-L1Spearman correlation coefficient
2019
Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports 2019, 9: 8572. PMID: 31189943, PMCID: PMC6561945, DOI: 10.1038/s41598-019-42784-9.Peer-Reviewed Original ResearchConceptsBreast cancer skin metastasesBreast cancer metastasisSkin metastasesImmune responsePost-treatment tumor samplesCancer metastasisReceptor 7 agonistStrong T-helperDurable clinical responsesImmune effector functionsBasal cell carcinomaRobust immune responseTopical imiquimodClinical responseT helperTumor rejectionCell carcinomaCytotoxic functionTranscriptomic profilesTumor regressionClinical trialsAntigen presentationT cellsImiquimodTumor destruction
2014
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology
Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, de Guzman Strong C, Gonzalez J, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal Of Allergy And Clinical Immunology 2014, 133: 1626-1634. PMID: 24786238, PMCID: PMC4122665, DOI: 10.1016/j.jaci.2014.03.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBiomarkersCluster AnalysisCyclosporineDendritic CellsDermatitis, AtopicEpidermisFemaleGene Expression ProfilingGene Expression RegulationHumansHyperplasiaImmunosuppressive AgentsInflammationMaleMiddle AgedPhenotypeSignal TransductionT-Lymphocyte SubsetsTreatment OutcomeYoung AdultConceptsClinical improvementAtopic dermatitisCytokine activationEpidermal alterationsAD skin lesionsEpidermal pathologyWeeks of treatmentT cell cytokinesCommon inflammatory diseaseSystemic immunosuppressantsSCORAD scoreNonlesional skinWeek 12Inflammatory pathwaysTissue inflammationBiopsy specimensInflammatory diseasesSignificant gene expression changesSevere diseaseEpidermal hyperplasiaImmunohistochemistry studiesSkin lesionsSpecific cytokinesWeek 2CsA effects